

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

**RESIGNATION OF NON-EXECUTIVE DIRECTOR AND
CHANGE IN THE COMPOSITION OF BOARD COMMITTEE**

Reference is made to the announcement of the Company dated December 13, 2022 (the “**Announcement**”) that Ms. Li Quan has tendered her resignation as a non-executive Director and a member of the Audit Committee with effect from December 19, 2022. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board hereby announces that Ms. Lin Shirley Yi-Hsien has been appointed as a member of the Audit Committee with effective from December 19, 2022. Ms. Lin Shirley Yi-Hsien currently is a non-executive Director of the Company.

The Board would like to take this opportunity to express its gratitude to Ms. Li Quan for her contribution and service to the Company during her tenure of office and welcome Ms. Lin Shirley Yi-Hsien to the Audit Committee.

By order of the Board

SciClone Pharmaceuticals (Holdings) Limited

ZHAO Hong

Executive Director, Chief Executive Officer and President

Hong Kong, December 19, 2022

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*